District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
09/29/2023
Locations: Sage Investigational Site, Washington, District of Columbia
Conditions: Huntington Disease
Post-Approval Study of the TREO Abdominal Stent-Graft System
Recruiting
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Medstar Washington Hospital Center, Washington, District of Columbia
Conditions: Abdominal Aortic Aneurysm
SPR PNS for Chronic Shoulder Pain
Recruiting
The purpose of this research is to gather post-market data regarding the effectiveness of the SPRINT Peripheral Nerve Stimulation (PNS) System for the treatment of chronic shoulder pain due to chronic degenerative changes of your shoulder. The System delivers mild electrical stimulation to the muscles in your shoulder. The System includes up to two leads (small wires) that are placed through your skin into your shoulder. The leads attach to a device worn on your body that deliver stimulation (ca... Read More
Gender:
All
Ages:
Between 21 years and 100 years
Trial Updated:
09/26/2023
Locations: International Spine Pain & Performance Center, Washington, District of Columbia
Conditions: Shoulder Pain, Shoulder Injuries, Shoulder Arthritis
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population. The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
All
Ages:
Between 5 years and 14 years
Trial Updated:
09/26/2023
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Obesity, Childhood, Cancer, Survivorship
Local Anesthesia Before Bulkamid Injection
Recruiting
While recommended pre-anesthesia for polyacylamide hydrogel (PAHG, Bulkamid) injections for stress urinary incontinence and intrinsic sphincter deficiency can include intraurethral anesthetic gel with or without periurethral block, there is no existing literature to guide choice of anesthesia. This is a single-blinded randomized control trial to evaluate post-procedure pain with choice of anesthesia before PAHG injection.
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Stress Urinary Incontinence, Intrinsic Sphincter Deficiency
Continuous Assessment of Hemodynamic Compensation in Pediatric Trauma Patients
Recruiting
This is an observation study using the Flashback CRI T1 tablet to collect data on compensatory reserve index in pediatric trauma patients. Highest trauma activations at the institution will be enrolled in the study and data will be collected for 12-24 hours based on the patient's hemodynamic status. The device collects data via a pulse oximeter probe. No treatment decisions will be made based on the values of the on the CRI tablet. Data will be retrospectively reviewed to determine if any trends... Read More
Gender:
All
Ages:
Between 31 days and 26 years
Trial Updated:
09/25/2023
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Trauma
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
Recruiting
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/22/2023
Locations: Georgetown University, Washington, District of Columbia
Conditions: Breast Cancer, Triple Negative Breast Cancer
Reshaping Postpartum Follow-up
Recruiting
The aim of this study is to evaluate the impact of personalized postpartum follow-up cards on completion of postpartum health related tasks. The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. Participants will be randomized to this intervention or the control group, which will consist of standard education ro... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Washington Hospital Center, Washington, District of Columbia
Conditions: Hypertension in Pregnancy, Gestational Diabetes, Cervical Dysplasia
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
Recruiting
This is a phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy for patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy. Conventional therapy may include chemotherapy, surgery, radiation, autologous stem cell transplant, or targeted therapy.
Gender:
All
Ages:
Between 6 years and 70 years
Trial Updated:
09/19/2023
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Solid Tumor
Multi-antigen T Cell Infusion Against Neuro-oncologic Disease
Recruiting
This Phase I dose-escalation trial is designed to determine the safety and feasibility of rapidly generated tumor multi-antigen associated specific cytotoxic T lymphocytes (TAA-T) in patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). Pediatric and adult patients who have high-risk CNS tumors known to typically have positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME... Read More
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
09/19/2023
Locations: Brain Tumor Institute, Children's National Medical Center, Washington, District of Columbia
Conditions: Brain Tumor
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
Recruiting
This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV) injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size 2, with the first cohort treated at the lowest dose level 1, all successive doses chosen by the EffTox method, and no untried dose level skipped when escalating. The scientific goal of the trial is to determine an optimal IV-CTL cell... Read More
Gender:
All
Ages:
All
Trial Updated:
09/19/2023
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Viral Infection
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Recruiting
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment of high-risk or relapsed or refractory hematopoietic malignancies. In addition to safety, this study will also evaluate if event-free survival (EFS) is improved with TAA-T administration at six months after HSCT for patients with high risk AML and M... Read More
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
09/19/2023
Locations: Childrens National Medical Center, Washington, District of Columbia
Conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS